Whole-cell cancer immunizations yielded DR5 mAbs with desirable binding and functional properties. • Incorporation of anti
Synaffix expands collaboration with MacroGenics
Antibodies | Free Full-Text | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
DART Protein Shows Potential as Shock-and-Kill Strategy Against HIV | Duke Health
MacroGenics: A Look At The DART Platform (NASDAQ:MGNX) | Seeking Alpha
MacroGenics: королева биспецифических моноклональных антител | МОСМЕДПРЕПАРАТЫ
Document
Cell-Line Development: Where Nature Meets Nurture
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies | BioDrugs
MacroGenics Provides Corporate Update | citybiz
SEC Filing | MacroGenics, Inc.
Tuning Up or Taming Immune Responses
The structures of diabody, DART ® , and TandAb fragments. (A) A... | Download Scientific Diagram
mgnx-20211231
MacroGenics Advances Two First-in-Class Clinical DART® Molecules
MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
Document
The development and structure of Tebotelimab using DART® technology.... | Download Scientific Diagram
SEC Filing | MacroGenics, Inc.
Platforms – MacroGenics
JCI - Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells
Multispecific, Multivalent Antibody‐Based Molecules Engineered on the DART® and TRIDENTTM Platforms - Huang - 2020 - Current Protocols in Immunology - Wiley Online Library
BI Taps MacroGenics in Multibillion-Dollar Deal for Antibody Development
MacroGenics Enters Research Collaboration with Janssen to
